Clinical Trial on Atopic Dermatitis, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa (HS) - Clinical Trials Registry

Study Overview

Status

Recruiting

Conditions

Detailed Description

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them. TARGET-DERM+ is designed to develop a large, robust database of real-world data regarding the natural history, management, and health outcomes related to the care of DD of diverse etiologies and practice settings. The study is also designed to establish learning health networks focused on quality of care for patients with DD.

Study Type

Observational

Enrollment (Estimated)

2000000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Lynda Lee Burch
Phone Number: 9842340268
Email: lburch@pedestalhealth.com

Study Contact Backup

Name: Danisha Devane
Phone Number: 9842340268
Email: ddevane@pedestalhealth.com

Study Locations

United States
- North Carolina
  - Winston-Salem, North Carolina, United States, 27157
    - Recruiting
    - Wake Forest University Health Science
    - Principal Investigator:
      
      Steven Feldman, MD
    - Contact:
      
      Irma Richardson
      
      Phone Number: 336-716-7740
      
      Email: Irma.Richardson@advocatehealth.org
- Pennsylvania
  - Philadelphia, Pennsylvania, United States, 19104
    - Recruiting
    - University of Pennsylvania
    - Principal Investigator:
      
      Joel Gelfand, MD
- South Carolina
  - Charleston, South Carolina, United States, 29407
    - Recruiting
    - Medical University of South Carolina
    - Contact:
      
      Courtney Rowley
      
      Phone Number: 843-792-9784
      
      Email: rowle@musc.edu
    - Contact:
      
      Patrick Cote
      
      Phone Number: 843-792-3746
      
      Email: cotp@musc.edu
    - Principal Investigator:
      
      Lara Wine-Lee, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

2,000,000

Description

Inclusion Criteria:

Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.

Exclusion Criteria:

Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Disease Cohort Adult patients and patients under the age of majority with a diagnosis of DD by ICD or other relevant healthcare code in the EHR interface.
Engaged Cohort Adult patients and patients under the age of majority diagnosed and managed for DD invited to participate OR HCPs who treat patients with these conditions. Informed consent is required for all participants in an Engaged Cohort. Willing to complete required Engaged Cohort activities.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease Time Frame: 15 years	The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD	15 years
To characterize the natural history of disease in patients with dermatologic disease from various etiologies Time Frame: 15 years	A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.	15 years
To establish learning health networks focused on quality of care for patients Time Frame: 15 years	Identify deficiencies and best practices in care of patients with DD. • Evaluate outcomes from targeted learning content in the management of patients with DD.	15 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate provider management practices in the treatment of patients with DD Time Frame: 15 years	Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data.	15 years
To evaluate longitudinal and patient reported outcomes in DD Time Frame: 15 years	Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health.	15 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Target PharmaSolutions, Inc.

Investigators

Study Director: Laura Dalfonso, Pedestal Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

August 3, 2041

Study Completion (Estimated)

August 3, 2041

Study Registration Dates

First Submitted

July 21, 2026

First Submitted That Met QC Criteria

July 31, 2026

First Posted (Actual)

August 5, 2026

Study Record Updates

Last Update Posted (Actual)